The Chumakov Center, which developed the CoviVac vaccine, does not exclude the involvement of partners if there is a need to scale up the production of the drug, TASS reports with reference to Konstantin Chernov, Director of Development of the Center.
“We are thinking about it. In September, we installed additional equipment and launched it, raising the production capacity for Covivak several times. Now, as you can see, we do not make groundless promises, we only report on what we have done. We are studying the options for capacity increase in the case there is a need to increase production, even several times. And in this case, indeed, we will need some kind of partner, but this is also determined from the point of view of expediency. We cannot invest ourselves and promise anything to a partner unless we understand that the product will be in demand on the local or international market,” Chernov said.
The inactivated whole-virion vaccine CoviVac developed at the Chumakov Center was registered by the Ministry of Health of Russia on February 19. In early October, it was reported that the biopharmaceutical company Nanolek intends to start producing CoviVac in November.
